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Targeted therapies designed to exploit specific
molecular pathways in aggressive cancers are an
exciting area of current research. Mixed Lineage
Leukemia (MLL) mutations such as the t(4;11)
translocation cause aggressive leukemias that
are refractory to conventional treatment. The
t(4;11) translocation produces an MLL/AF4 fusion
protein that activates key target genes through
both epigenetic and transcriptional elongation
mechanisms. In this study, we show that t(4;11)
patient cells express high levels of BCL-2 and
are highly sensitive to treatment with the BCL-2-
specific BH3 mimetic ABT-199. We demonstrate
that MLL/AF4 specifically upregulates the BCL-2
gene but not other BCL-2 family members via
DOT1L-mediated H3K79me2/3. We use this infor-
mation to show that a t(4;11) cell line is sensitive
to a combination of ABT-199 and DOT1L inhibi-
tors. In addition, ABT-199 synergizes with stan-
dard induction-type therapy in a xenotransplant
model, advocating for the introduction of ABT-
199 into therapeutic regimens for MLL-rearranged
leukemias.Cell RepINTRODUCTION
Mixed-lineage-leukemia (MLL) is one of the most frequently
translocated genes (MLL-rearranged or MLLr) in hematologic
malignancies and produces aggressive leukemias where more
targeted therapeutic approaches are particularly needed. Trans-
location t(4;11)(q21;q23) generates MLL/AF4 and AF4/MLL
fusion products, both of which function as transcriptional activa-
tors. The role of AF4/MLL in t(4;11) leukemias is controversial, as
it has transformation potential (Bursen et al., 2010) but is not ex-
pressed in all t(4;11) patients (Andersson et al., 2015).
Conversely, the MLL/AF4 fusion protein is expressed in all
t(4;11) patients, and knockdowns of MLL/AF4, even in the pres-
ence of AF4/MLL, are sufficient to stop t(4;11) leukemias from
growing (Thomas et al., 2005).
t(4;11) leukemias are diagnosed mainly as precursor B cell
acute lymphoblastic leukemia (B-ALL) in both infants, children,
and adults, and they predict poor long-term outcomes, even
with aggressive chemotherapy or therapy combined with
stem cell transplantation (Beldjord et al., 2014; Dreyer et al.,
2015; Pieters et al., 2007). t(4;11) leukemias have very few co-
operating mutations, especially in infants (Andersson et al.,
2015), suggesting that MLL/AF4 is the primary driver of
continued leukemogenesis. Therefore, understanding the func-
tion of the MLL/AF4 fusion protein and the genes that it regu-
lates will be essential for the development of targeted t(4;11)











































N =      9       53     16     2      23     40    2     47      2      12      1     Figure 1. RPPA Profiling of BCL-2 Proteins in
ALL, Showing Heatmaps of Differentially Ex-
pressed Proteins Based on Cytogenetics
Black bars indicate 8q24 leukemia samples and their
expression patterns are shown in the blue dashed line
box. Yellow bars indicate t(4;11)-positive samples, and
their expression patterns are shown in the red dashed
line box.
See also Figure S1.BCL-2 family proteins mediate an intrinsic, mitochondrial
apoptosis pathway. BCL-2, BCL-XL, and MCL-1 are anti-
apoptotic BCL-2 family proteins, while BCL-2 homology 3
(BH3) proteins BIM, BID, BAD, NOXA, PUMA, and HRK are
pro-apoptotic proteins that trigger cell death. Previous studies
demonstrated high expression of BCL-2 in MLLr pediatric ALL
(Robinson et al., 2008). Using chromatin immunoprecipitation
sequencing (ChIP-seq), we and others have detected direct
binding of MLL/AF4 (Guenther et al., 2008; Wilkinson et al.,
2013) to the BCL-2 gene. This suggests, but does not
completely establish, that MLL/AF4 and other fusion proteins
could be the cause of increased BCL-2 levels through direct
upregulation of BCL-2 transcription. Supporting the potential
importance of this observation, activity of the first-generation
BCL-2 antagonists has indicated that BCL-2 inhibition could
be exploited for MLLr leukemias (Robinson et al., 2008; Ur-
tishak et al., 2013). ABT-199/GDC-0199 (venetoclax) is a BH3
mimetic that specifically targets BCL-2 while sparing BCL-XL,
thus avoiding thrombocytopenia (Chonghaile et al., 2014; Pan
et al., 2014; Souers et al., 2013; Vaillant et al., 2013; Vanden-
berg and Cory, 2013). ABT-199 has achieved promising anti-
leukemia activity in patients with chronic lymphocytic leukemia
(CLL) (Molica, 2015), and it has been reported to have preclin-
ical activities in estrogen-receptor-positive breast cancer,
acute myeloid leukemia (AML), early T cell progenitor leukemia,
Myc-driven B cell lymphomas, and acute lymphoblastic leuke-
mia (Alford et al., 2015; Chonghaile et al., 2014; Pan et al.,
2014; Souers et al., 2013; Vaillant et al., 2013; Vandenberg
and Cory, 2013).
Recruitment of P-TEFb (a heterodimer consisting of Cyclin T1
or T2 and the CDK9 kinase) and transcription elongation factors
such as ENL and AF9 (Lin et al., 2010; Mueller et al., 2007; Yo-
koyama et al., 2010) are thought to be major ways in which2716 Cell Reports 13, 2715–2727, December 29, 2015 ª2015 The AuthorsMLL/AF4 activates gene targets. Other mech-
anisms have been proposed, including an
ENL/AF9 direct interaction with the polycomb
group (PcG) protein CBX8 (Maethner et al.,
2013). In addition, ENL and AF9 interact
directly with DOT1L (Biswas et al., 2011;
Leach et al., 2013; Mohan et al., 2010), a his-
tone methyltransferase that specifically meth-
ylates lysine 79 on histone 3. Since ENL or
AF9 and DOT1L exist in a separate, distinct
complex from MLL/AF4 (Biswas et al., 2011;
Leach et al., 2013), it is unclear whether or
how MLL/AF4 has any direct effect on recruit-
ment of the DOT1L protein, but increased
H3K79me2/3 levels are strongly associated with MLL/AF4
binding and with high levels of gene activation (Krivtsov et al.,
2008).
In this study, we explored the dependence of ALL subtypes
on BCL-2 family proteins and examined the antitumor efficacy
of ABT-199 in ALL, with a special focus on the MLLr types.
Our findings indicate that direct transcriptional upregulation of
BCL-2 by MLL/AF4 confers sensitivity to the selective BCL-2
antagonist ABT-199. We also show that MLL/AF4 promotes
high levels of BCL-2 expression by binding directly to the locus
and keeping it active via maintenance of H3K79me2/3 without
affecting P-TEFb recruitment. This MLL/AF4 regulatory activity
is specific to BCL-2 and has no effect on other BCL-2 family
members. This led to the finding that the DOT1L inhibitors
sensitize MLLr leukemias to BCL-2 inhibition with ABT-199.
Importantly, we were also able to show that ABT-199 synergizes
with standard-induction-type chemotherapeutic agents, sug-
gesting that ABT-199 could be a useful addition to MLLr thera-
peutic regimens.
RESULTS
t(4;11) ALL Is Associated with High Levels of BCL-2,
BAX, and BIM
Expression of 12 pro- and anti-apoptotic proteins was studied
in 186 ALL cases by reverse-phase protein analysis (RPPA).
Supervised clustering demonstrated distinct differences in
acute lymphoblastic leukemia (ALL) with different cytogenetic
characteristics (p < 0.005; false discovery rate [FDR], <0.2%).
Patients with 8q24 (CMYC) translocation (Figure 1; n = 9) ex-
pressed low levels of BCL-2 and BAX while maintaining high
expression of BIM and intermediate levels of MCL-1. No spe-
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Figure 2. MLL-AF4 Binds to the BCL-2 Gene
and Keeps It Active
(A) Schematic of MLL/AF4 direct interactions and
mutually exclusive complexes (dotted arrows).
Gene activation could occur (1) by promoting
H3K79 methylation, (2) by inhibiting CBX8 activity,
or (3) AF4/AFF4 direct recruitment of P-TEFb (ie.
Cyclin T1 and CDK9) and serine 2 phosphorylation
of RNA polymerase II.
(B) ChIP-seq and ATAC-seq peaks in SEM cells
across the BCL-2 locus. PCR primers (1–6) used in
subsequent experiments are shown as yellow ar-
rowheads. P, promoter; E, enhancer.
(C) BCL-2 is ranked 8,381 out of 8,647 genes (top
5%) marked with H3K79me2 in SEM cells.
(D) Real-time PCR for different targets in SEM cells
treated with either a control (black bars) or anMLL-
AF4-specific siRNA (gray bars). Signal was
normalized to control treated cells and is the
average of five independent knockdown experi-
ments. Error bars indicate SD. *p < 0.02.
(E) Western blots for the indicated proteins in SEM
cells treated with either a control () or MLL-AF4
specific (+) siRNA.
(F–H) ChIP experiments (the average of three to
five independent knockdowns) for MLL(N), AF4(C),
ENL, AF9, AFF4, or CDK9 in SEM cells treated with
either control (dark colored bars) or MLL-AF4
siRNAs (light colored bars). PCR primers are as
indicated in (A). A9 = a primer set in the well-known
MLL/AF4 target gene HOXA9, used as a positive
control for ChIP. Error bars indicate SEM.
See also Figure S2.t(4;11) (n = 12) expressed high levels of BCL-2, BAX, and BIM
(Figure 1) but relatively low levels of BCL-XL and MCL-1,
although the latter differences did not reach statistical
significance.
To investigate whether high BCL-2 protein levels in MLLr ALL
is associated with high transcript levels of BCL-2, gene expres-
sion microarray data from three large cohorts of patients with
ALL were analyzed (Figure S1): the St. Jude Children’s Research
Hospital pediatric ALL clinical trial cohort; the Eastern Coopera-Cell Reports 13, 2715–2727, Detive Oncology Group (ECOG) Clinical Trial
E2993, and the Children’s Oncology
Group (COG) Clinical Trial P9906. BCL-2
mRNA expression was significantly
higher in MLLr samples than in normal B
cell controls in the St. Jude cohort (p =
0.015). BCL-2 mRNA expression levels
were significantly higher in theMLLr sam-
ples than in the E2A/PBX1 samples in
all three cohorts (p = 0.015 for ECOG
E2993, 0.0005 for COG P9906, and
0.002 for St. Jude’s) and higher than in
molecularly undesignated B-ALL samples
in the COG P9906 study (p = 0.01). These
results suggest that BCL-2 is highly ex-
pressed in t(4;11) and other MLLr ALLand, therefore, that BCL-2 is a potential therapeutic target in
these ALL subtypes.
MLL/AF4 Directly Controls Activation of theBCL-2Gene
Confirming previously published data (Guenther et al., 2008; Wil-
kinson et al., 2013), ChIP-seq using an MLL N-terminal antibody
(Ab) (MLLN) and an AF4 C-terminal Ab (AF4C) in the MLL/AF4-
positive B-ALL cell lines SEM and RS4;11 shows that MLL/AF4
binds to the BCL-2 locus (Figure 2B; Figure S2A). ChIP-seq forcember 29, 2015 ª2015 The Authors 2717
specific MLL/AF4 complex components (summarized in Fig-
ure 2A) shows that ENL binding closely matches the profile of
MLL/AF4 binding, while H3K79me2/3 creates a broad domain
across the locus (Figure 2B). Comparable to two canonical
MLL/AF4 target genes, BCL-2 is a typical MLL/AF4 target gene
in that it is markedwith very high levels of H3K79me2 (Figure 2C).
A potential downstream enhancer—identified by its enrichment
for H3K4me1, H3K27Ac, and the presence of ATAC sequencing
(ATAC-seq) peaks—is also bound by theMLL/AF4/ENL complex
(Figure 2B, blue shaded region marked with an E). A peak of
H3K4me3 and binding of the SET1 complex (CFP1) are detected
at the BCL-2 promoter (Figure 2B), suggesting that the locus
could also be regulated by H3K4 methyltransferase complexes.
For a functional analysis of MLL/AF4 activity, SEM and RS4;11
cells were treated with unique MLL/AF4-specific small inter-
fering RNAs (siRNAs) (Thomas et al., 2005). MLL/AF4 siRNA
knockdowns led to a reduction of BCL-2 gene expression that
was comparable to that of HOXA9 and RUNX1 (Figure 2D; Fig-
ure S2B) and also resulted in reduced BCL-2 protein levels in
replicate experiments (Figures 2E and S2C). MLL/AF4 siRNA
treatment also reduced MLL/AF4 binding to BCL-2 (Figures 2F
and S2D) without affecting wild-type MLL levels (Figures 2D,
2E, and S2B) or wild-type MLL or AF4 binding to BCL-2 (Fig-
ure S2E). Conversely, wild-type MLL knockdowns had no effect
on BCL-2 expression (Figure S2F), indicating that MLL/AF4
directly activates BCL-2 while wild-type MLL is dispensable for
BCL-2 activation in t(4;11) cells.
MLL/AF4 knockdowns were associated with reduced ENL
binding to BCL-2 in both SEM and RS4;11 cells (Figures 2G
and S2D), but there was only a marginal effect on AF9 binding,
especially compared to HOXA9 (Figure 2G). ENL mRNA levels
are unaffected by MLL/AF4 knockdowns (Figure 2D), but ENL
protein levels are reduced (Figure 2E), suggesting that the direct
interaction between MLL/AF4 and ENL may somehow stabilize
the ENL protein. In contrast to the results observed with ENL,
no effect was seen on the binding of AFF4, CDK9, or Cyclin T1
in SEM cells (Figures 2H and S2G), suggesting that MLL/AF4-
mediated activation of BCL-2 does not occur through P-TEFb
recruitment and stabilization. Although CBX8 binding was easily
detected at HOXC8 (a known Polycomb target in SEM cells), no
change in CBX8 binding was seen at BCL-2 (Figure S2H).
Instead, MLL/AF4 knockdowns were associated with a loss of
DOT1L binding at BCL-2 (Figure S2I). Together, these results
suggest that neither pathway 2 nor pathway 3 (see Figure 2A)
are important components of MLL/AF4-mediated regulation of
BCL-2 but that MLL/AF4, instead, stabilizes both ENL and
DOT1L binding (pathway 1) at BCL-2.
MLL/AF4 Controls BCL-2 Gene Activation by Promoting
Increased H3K79me2/3 Levels
To explore MLL/AF4 function further, we performed ChIP for
several different histone marks in MLL/AF4 knockdowns.
Consistent with the observed loss of DOT1L binding, both
H3K79me2 and me3 levels are reduced across BCL-2 (Fig-
ure 3A). We also observed reductions of H3K27Ac, especially
at the downstream enhancer region of BCL-2 (Figure 3B),
whereas no significant changes in H3K4me3 levels were seen
(Figure 3C).2718 Cell Reports 13, 2715–2727, December 29, 2015 ª2015 The AuTo determine whether reduction of H3K79me2/3 levels alone
could impact expression of BCL-2 or other gene targets, SEM
cells were treated with either 2 mMor 5 mMof the DOT1L inhibitor
EPZ5676 for 7 days. TheMLL/AF4 target genesHOXA9,RUNX1,
and BCL-2 (but not any other BCL-2 family members) all showed
reduced expression with the 2- and 5-mM treatment at day 7 (Fig-
ure 3D), and this correlated with a loss of H3K79me2/3 globally
and at the BCL-2 and HOXA9 loci (Figures 3E and 3F). Although
both the 2-mM and 5-mM treatments impacted BCL-2 expres-
sion, only the 5-mM treatment produced an observable reduction
in BCL-2 protein levels (Figure 3E), comparable to that seen
when BCL-2 is directly targeted with siRNAs that can disrupt
leukemic growth (Figures S3A and S3B). Together with the
data in the previous section, these results indicate that the pri-
mary way that MLL/AF4 controls activation of BCL-2 is through
maintaining H3K79Me2/3 levels (see Figure 3G for a summary).
To determine whether DOT1L activity and BCL-2 inhibition
were cooperative, we examined growth-inhibitory activity of
two structurally distinct DOT1L inhibitors, SGC0946 and
EPZ5676, combined with the selective BCL-2 inhibitor ABT-
199. Consistent with our aforementioned results using 2 mM
EPZ5676, treatment with 1 mM EPZ5676 had very little detect-
able effect on BCL-2 family protein levels (Figure S3C). However,
a combined blockade of DOT1L and BCL-2 demonstrated
deeper growth-inhibitory effects in t(4;11) SEMK2 cells (Fig-
ure 3H) but not in the non-MLLr cell line Nalm-6 (Figure S3D).
In SEM cells, MLL/AF4 is bound to both MCL-1 and BIM, but
not BAX or BCL-2L1 (Figures 4A and 4B), and BCL-2 family
members are associated with a range of H3K79me2/3 levels
(Figures 4A–4C). MLL/AF4 knockdowns have little effect on
ENL or H3K79me3 levels at these loci (Figure 4B), and there is
no effect on the expression levels of MCL-1, BIM, BAX, or
BCL-2L1 (Figures 4D and 4E). Together, these data suggest
that MLL/AF4 specifically activates BCL-2 by promoting
increased H3K79me2/3 levels, while other BCL-2 family mem-
bers are not dependent on MLL/AF4 or H3K79me2/3 for their
expression, even though BIMandBAX are both highly expressed
in t(4;11) patient samples.
BH3Profiling Demonstrates BCL-2 Dependence ofMLLr
Primary ALL
ABT-199 is a BCL-2-selective inhibitor recently shown to be
active in ALL (Alford et al., 2015). In bimolecular fluorescence
complementation (BiFC) assays (Figure 5A; Vela et al., 2013),
ABT-199 inhibited BCL-2/BIM interactions, and ABT-737 in-
hibited the interactions of BCL-2 and BCL-XL with BIM, accord-
ing to the known specificity of these inhibitors. BH3 profiling is
a technique that identifies the BCL-2 protein family addictions
of cancer cells based on the selective binding of BH3 proteins
to specific anti-apoptotic BCL-2 family proteins (Certo et al.,
2006; Chonghaile et al., 2014; Pan et al., 2014). Using ALL blast
mitochondria from 16 samples consisting of primary ALL cells
or patient-derived xenografts, we found a statistically signifi-
cant correlation between mitochondrial sensitivity to BAD
BH3 peptide (indicating BCL-2, BCL-XL, or BCL-W depen-
dence) and cell viability determined by half-maximal inhibitory
concentration (IC50) values of ABT-199 (Figure 5B; Table S2).
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ABT-199 ABT-199 + SGC0946 1µM
180.9 17.65 IC50
ABT-199 ABT-199 + EPZ5676 1µM
26.3 8.33
Figure 3. MLL-AF4 Keeps BCL-2 Active by
Promoting H3K79me2/3
(A–C) ChIP experiments (average of four indepen-
dent knockdowns) for H3K79me2, H3K79me3,
H3K27Ac, or H3K4me3 in SEM cells treated with
either control (dark bars) orMLL-AF4 siRNAs (light
bars). PCR primers are as in Figure 1. Error bars
indicate SEM. rel, relative; neg, negative.
(D) SEM cells treated with 2 mM or 5 mM EPZ5676
for 7 days were subjected to real-time RT-PCR
with the primers/probe sets indicated. Error bars
indicate SD of four PCR replicates.
(E) Western blots of SEM cells treated with 2 or
5 mM EPZ5676 for 7 days.
(F) H3K79me3 ChIP at the BCL-2 and HOXA9 loci
in 5 mM EPZ5676-treated SEM cells.
(G) A proposed model where MLL/AF4 stabilizes
ENL protein levels and creates a local concentra-
tion of ENL that allows for dynamic exchange
between an MLL-AF4:ENL complex and a DOT1L:
ENL complex, potentially increasing H3K79me3
levels at the locus.
(H) SEM cells were co-treated with 1 mM of DOT1L
inhibitors SGC0946 or EPZ5676 and increasing
concentrations of ABT-199 (50 nM, 100 nM, and
150 nM) for 4 days (SGC0946) or 7 days (EPZ5676).
Error bars indicate SEM.
See also Figure S3.BCL-XL-selective HRK, MCL-1-selective NOXA, or pan-BCL-2
family BIM BH3 peptides (Figure 5B). Similar correlations were
obtained in a different set of adult and pediatric B-ALL sam-
ples treated with ABT-737 (Figure S4A). Next, we plotted
sensitivity to the BAD BH3 peptide against sensitivity to the
HRK peptide (Figure 5C). Five of the six MLLr samples and
additional four B-ALL samples showed BCL-2 dependency
(shaded area).
MLLr Cells Expressing High Levels of BCL-2 Are
Susceptible to ABT-199-Induced Apoptosis In Vitro and
to a Combination of ABT-199 with Chemotherapy
Our gene transcription studies and functional BH3 profiling pre-
dict that MLLr ALL will be particularly dependent on BCL-2 for
survival. In a series of genetically diverse ALL cell lines, two
t(4;11)-positive cell lines, RS4;11 and SEM-K2, exhibited high
sensitivity to ABT-199 (Figures 5D and S4B). BCL-2 protein
expression was highest in MLLr RS4;11 and SEMK2 togetherCell Reports 13, 2715–2727, Dewith the pro-B ALL cell line REH; and
BCL-2, but not MCL-1 or BCL-XL, expres-
sion correlatedwith sensitivity to ABT-199
(r = 0.82, p = 0.008) (Figures 5E and
S4C). In a panel of 24 primary ALL sam-
ples, 92% were sensitive to ABT-199
(IC50 < 1 mM; Figures 5F and S4D), and
78% were sensitive to ABT-737. Interest-
ingly, all five MLLr samples—four t(4;11)
cases and one t(9;11) case—had ICs50
%0.1 mM. Western blot analysis of ALL
blasts (n = 9) confirmed high BCL-2 pro-tein levels (Figure S4E). High sensitivity of primary B-ALL (non-
MLL) samples to BCL-2 inhibition was validated in a separate
cohort of adult and pediatric samples treated with ABT-199 or
dual BCL-2/BCL-XL inhibitor ABT-263 for 8 hr (Figure S4F).
In ALL cell lines (REH, SEMK2, and RS4;11), a combination of
ABT-737 or ABT-199 with chemotherapy agents (vincristine
[VCR], doxorubicin [DOX], dexamethasone [DEXA], cytarabine
[AraC], L-asparaginase [L-ASP])wascommonlysynergistic (Table
S3), with best responses observed upon combination with L-ASP
(combination index values, <0.01). In six primary ALL samples,
each combination produced significantly greater cytotoxic activ-
ity (Figures 6A and6B). Consistentwith the cell line data, the com-
bination of L-ASP with ABT-199 exhibited the greatest effect.
Treatment with L-ASP in ALL patients is able to induce
apoptosis specifically in lymphoblast cells. We reasoned that
the nature of the L-ASP/ABT-199 synergistic interaction could
be due to enhancement of apoptotic pathways in MLL/AF4 cells.




Figure 4. MLL/AF4 Does Not Directly Acti-
vate Other BCL-2 Family Genes
(A) ChIP-seq and ATAC-seq peaks in SEM cells at
the loci indicated. BCL-2 tracks are also shown for
comparison purposes. PCR primers (1–15) used in
subsequent experiments shown by yellow arrow-
heads.
(B) ChIP experiments (average of three to five in-
dependent knockdowns) in SEM cells treated with
either control (dark colored bars) or MLL-AF4
siRNAs (light colored bars). PCR primers are as in
(A). BCL-2 and HOXA9 (A9) data are from Figure 2
and included for comparison purposes. Error bars
indicate SEM.
(C) The same H3K79me2 ranking graph as in Fig-
ure 2C, with BCL-2 family genes added for com-
parison purposes.
(D) Real-time PCR of samples from Figure 2D for
BCL-2 family genes. MLL-AF4, MLL, and BCL-2
expression data are from Figure 2D and included
for comparison purposes. Error bars indicate SD.
*p < 0.02.
(E) Western blots for the indicated proteins in SEM
cells treated with either a control () or MLL-AF4-
specific (+) siRNA. Results shown are from three
different biological replicates.cells treated with L-ASP, VCR, or DEXA showed that each treat-
ment significantly reduced the levels of anti-apoptotic proteins
MCL-1 and BCL-XL and the apoptotic factor FAS-associated
factor 1 (FAF1; Figure 6C). Interestingly, MLL/AF4 binds and ac-
tivates FAF1 expression (Figures 6D–6F), and although FAF1
does not appear to contribute to leukemic growth (Figure S5),
MLL/AF4 could contribute to high levels FAF1 protein in the
cell and sensitivity to apoptosis induction.2720 Cell Reports 13, 2715–2727, December 29, 2015 ª2015 The AuthorsABT-199 Attenuates Tumor Growth
ofMLLr precursor-B ALL In Vivo and
Enhances Anti-leukemia Effects of
Standard Chemotherapy
Next, we investigated the anti-leukemic
efficacy of ABT-199 in MLLr ALL in vivo
using primary ALL xenograft models. In
a highly aggressive primary xenograft
ICN3 model, there was a marked reduc-
tion of circulating CD19-positive cells af-
ter 4 days of treatment initiated on day
45 post-cell injection (Figure 7A). Despite
high levels of blasts in bone marrow (BM)
on day 10 due to rapid disease progres-
sion, half of the treated mice appeared
to benefit (Figure 7A). In the ALL-236-
GFP model, treatment with ABT-199 for
10 days reduced tumor burden measured
by bioluminescence or circulating GFP(+)
cells (Figures S6A and S6B).
Next, the anti-leukemic effects of ABT-
199 in combination with an induction-type
regimen, VXL, comprising VCR, L-ASP,
and DEXA, were evaluated in mice in-jected with cells from two t(4;11)-positive ALL patients (#542
and #682). Leukemic cells from both of these patients were
found to be BCL-2 dependent by BH3 profiling, with sample
#682 more sensitive to BIM peptide (Figure 7B). Leukemia
burden (human CD45-positive cells) was determined serially in
peripheral blood for case #682. Because case #542 showed a
more aggressive disease course, leukemia burden was deter-
mined only on day 42 of treatment.
Figure 5. BH3 Profiling Reveals BCL-2 Dependence in Primary ALL
(A) BiFC analysis of interactions of anti-apoptotic proteins with BIM. Results are expressed as the fold change induced by ABT-199/ABT-737 in Venus/RFP (red
fluorescent protein) ratio and are the mean ± SEM of three to six independent experiments. *p < 0.05; **p < 0.01.
(B) Levels of cytochrome c release frommitochondria of ALL cells exposed to the indicatedBH3peptideswere correlatedwith cell viability IC50 values for ABT-199.
(C) Cytochrome c release induced by BAD versus HRK peptides. The pink area represents probable BCL-2 dependence, and the blue area represents BCL-XL
dependence.
(D) IC50 values for ABT-199 and ABT-737 in ALL cell lines. MLL-rearranged ALL cell lines are shown in green (RS4;11) or red (SEMK2). ALL cell line cells were
treated with ABT-737 or ABT-199 for 48 hr, and the IC50 values calculated on the basis of viable (i.e., Annexin V-/PI-) cell numbers determined by flow cytometry.
(E) Sensitivity to ABT-199 correlates with endogenous BCL-2 protein levels but not with BCL-XL levels in ALL cell lines. Spearman correlations were calculated
based on protein expression levels relative to an internal control (b-actin) and then normalized to levels in NALM-6 cells.
(F) Primary ALL cells (n = 19) were treated with ABT-737 or ABT-199 for 24 hr, and the IC50 values were calculated as described earlier. MLLx,MLL-rearranged
xenograft samples.
See also Figure S4.In mice engrafted with #542, ABT-199 alone had minimal
effects on peripheral blood leukemia burden (Figure 7C). VXL
alone modestly reduced leukemia burden by 23% (p = 0.007).
Unexpectedly, the combination of ABT-199 with VXL reduced
leukemia burden >70% (p < 0.0001; Figure 7C), revealing striking
synergy in this ALL PDX model.
In case #682 mice, both VXL and ABT-199 showed anti-leuke-
mia effects (Figure 7D), consistent with higher sensitivity by BH3
profiling. On day 60 (Figure S6C), all six control mice carried
circulating human CD45-positive cells (mean ± SD, 81.8% ±
7.1%), while one mouse from each of the six treated with ABT-
199 and the six treated with VXL was leukemia free. Strikingly,Cell Repcirculating human CD45-positive cells were not detected in
any of the mice in the combination cohort up to day 69, although
positive cells were detected again on day 103 (data not shown).
Two mice in the combination-treatment group died from chemo-
therapy-related toxicity and infection but were leukemia-free on
autopsy.
DISCUSSION
Lymphoid malignancies utilize the anti-apoptotic BCL-2 family
proteins to maintain viability under conditions of oncogenic
stress. Because of this dependence, the leukemia cells areorts 13, 2715–2727, December 29, 2015 ª2015 The Authors 2721
Figure 6. ABT-199 in Combination with Chemotherapy Exhibits Cytotoxic Activity against Primary ALL Cells
(A and B) ALL primary samples (n = 6) and one sample from a patient with t(4;11) biphenotypic leukemia were treated with each single reagent or in combination
with ABT-199 at the following concentrations: ABT-199, 0.015 mM; AraC, 1 mM; DOX, 40 ng/ml; VCR, 1 ng/ml; and L-ASP, 5 U/ml. At 24 hr, viability (A) and cell
death (B) were determined by Annexin V and 7-AAD staining. Each dot represents one sample. Error bars indicate SEM. *p < 0.05.
(C) Western blot analysis of RS4;11 or SEMK2 cells left untreated (Ctr) or treated for 48 or 24 hr, respectively, with: L-ASP (ASP), 2 U or 5 U (RS4;11 or SEMK2,
respectively); VCR, 5 ng/ml; or DEXA, 1 mM. Representative blot of one of the three experiments that yielded similar results is shown.
(D–F)MLL/AF4 binds to the FAF1 gene (D), andMLL/AF4 siRNA treatment reducesMLL-AF4 binding to FAF1 (E) and reduces FAF1 protein levels (western blot, F).
Error bars in (E) represent SEM for three independent knockdown experiments.
See also Figure S5 and Table S3.susceptible to inhibition of anti-apoptotic BCL-2 family proteins.
It has been reported that the BCL-2/BCL-XL inhibitors ABT-737,
ABT-263, and ABT-199 induce rapid and robust apoptosis in
ALL cells, both in vitro (Alford et al., 2015; Del Gaizo Moore2722 Cell Reports 13, 2715–2727, December 29, 2015 ª2015 The Auet al., 2008; High et al., 2010) and in human-derived xenografts
(Suryani et al., 2014). In this context, we investigated the expres-
sion of BCL-2 family members in a large series of ALL patient
samples by proteomic profiling. In accordance with molecularthors
Figure 7. ABT-199 Attenuates Tumor Growth of MLLr Pre-B ALL and Interacts Synergistically with Induction-type Chemotherapy to Erad-
icate Patient-Derived ALL Cells In Vivo
(A) NSGmice were injected intravenously with ICN3 xenograft cells generated from a pediatric patient with relapsedMLL-rearranged pre-B-ALL. At day 45 post-
injection, mice were randomized into two treatment groups (n = 6 per arm): Vehicle only; ABT-199 at 100 mg/kg/day. Leukemia burden expressed as percent
human CD19+ cells is shown in peripheral blood (PB) on days 4 and 10 after treatment initiation and in BM and spleen on day 10. *p < 0.05; **p < 0.01.
(B) BH3 profiling of primary derived xenografts #542 and #682. Cytochrome c release in response to various concentrations of BH3 peptides and ABT-199.
(C and D) Leukemia cells from two patients with t(4;11) ALL (#542 and #682) were injected into NRG mice via tail vein. On day 24 post-engraftment, mice were
randomly divided into cohorts to receive VXL (VCR, DEXA, and L-ASP), ABT-199 alone, VXL+ABT-199 combination; or vehicle controls (n = 6 per arm).
(C) Percentage of circulating ALL cells on day 42 post-engraftment in case #542. (D) Time course changes in percentages of circulating ALL cells in case #682.
Leukemia progression was evaluated by determining the percentage of circulating human CD45-positive cells across different treatment groups. Error bars
indicate SD.
See also Figure S6.heterogeneity of ALL, the proteomic profiles were widely
dispersed but closely associated with cytogenetic abnormal-
ities. t(4;11) ALL was closely associated with high levels of
BCL-2, BAX, and BIM. BCL-2 has been previously implicated
in the pathogenesis of MLLr leukemias, and disruption of MLL-
fusion-driven BCL-2 expression has been proposed as a major
mechanism of action for the bromodomain inhibitor I-BET151
(Dawson et al., 2011). Examination of publicly available gene
expression datasets demonstrated that pediatric MLLr ALL ex-
presses high BCL-2mRNA levels, consistent with previous find-
ings in a smaller subset of pediatric ALL patients (Robinson et al.,
2008). In this study, we demonstrate a direct role for MLL/AF4 in
maintainingBCL-2 expression, providing a plausible explanation
for dependency of MLLr ALL cells on BCL-2 anti-apoptotic
activity.
Interestingly, althoughwe show thatBCL-2 expression isMLL/
AF4 dependent, other BCL-2 family members such as MCL-1,
BIM, BAX, and BCL-2L1 show no direct dependence on MLL/
AF4 for their expression. This is despite the fact that we detectCell Replow levels of MLL/AF4 binding and H3K79me2 at both the
MCL1 and the BIM genes. These results highlight the fact that
it is important to functionally validate ChIP-seq experiments,
since the presence of binding is not necessarily functionally rele-
vant. Importantly, we also show that wild-type MLL has no direct
role in activating BCL-2 in t(4;11) cells, indicating that BCL-2
overexpression is an MLL/AF4-specific regulatory event. There-
fore, treatment with BCL-2 inhibitors targets a direct pathway of
the MLL/AF4 driver mutation, indicating that this could be a spe-
cific vulnerability of these poor-prognosis t(4;11) leukemias.
Although the correlation between MLL/AF4 binding and
H3K79 methylation levels has been observed before (Guenther
et al., 2008; Krivtsov et al., 2008; Wilkinson et al., 2013), there
was previously little direct evidence that MLL/AF4 acted primar-
ily through H3K79me2/3 levels. Instead, past work has sug-
gested that MLL/AF4 functions primarily by recruiting a large
transcription elongation complex that includes AFF4, P-TEFb,
ENL, AF9, and other proteins (Lin et al., 2010; Mueller et al.,
2007; Yokoyama et al., 2010). It is unknown what the exactorts 13, 2715–2727, December 29, 2015 ª2015 The Authors 2723
role of H3K79me2/3 is, but recent work has suggested that it
functions, in part, by disrupting SIRT1-mediated silencing
(Chen et al., 2015). DOT1L inhibitors were able to reduce BCL-
2 expression, whileMCL1, BIM,BAX, andBCL-2L1 show almost
no sensitivity to DOT1L inhibitors. This suggests that the role of
H3K79me2/3 is very gene and context specific and underscores
the importance of future work designed to further explore the
function of this important histone mark and the complexes that
regulate it.
The AF4 protein interacts directly with ENL, but the ENL:AF4
interaction and the ENL:DOT1L interactions are mutually exclu-
sive, so how could MLL/AF4 cause recruitment of DOT1L and
increased H3K79me2 levels? Structural analysis of the AF9-
DOT1L interaction has shown that AF9 (and, by extension,
ENL) interacts with AF4 and DOT1L through the same intrinsi-
cally disordered domain (Kuntimaddi et al., 2015; Leach et al.,
2013). Intrinsic disorder allows for rapid association kinetics
and the possibility of a rapid, dynamic exchange of binding part-
ners between ENL:AF4 and ENL:DOT1L. Thus, it is possible that
MLL/AF4 has a direct impact on binding of DOT1L by increasing
the local concentration of ENL and/or AF9 proteins. To fully un-
derstand this possibility, further work is needed that studies
the dynamic interactions of these protein complexes in vivo.
Our observation that treatment of SEM cells with DOT1L inhib-
itors appears to cooperate with ABT-199 treatment provides an
interesting proof of principle that DOT1L inhibitors could poten-
tially be used to sensitizeMLLr leukemias to treatment with ABT-
199. DOT1L inhibition affects gene targets other than BCL-2
(e.g., HOXA9 and RUNX1); therefore, the nature of this coopera-
tive effect could be due to a general inhibition of a range of
different MLL/AF4 targets rather than one or a few MLL/AF4 tar-
gets. However, this provides an important proof of principle that
combining inhibitors that target MLL/AF4 complex activity can
be used in combination with inhibitors of important MLL/AF4
target gene products.
Through BH3 profiling, we demonstrate the predominant
dependence ofMLLrB-lineage ALL cells on BCL-2, asmitochon-
drial sensitivity to BCL-2-selective BAD peptide was more potent
than BCL-XL-selective HRK, MCL-1-selective NOXA, and non-
specific BIM peptide. Further, the robust response observed
upon treatment with the BAD peptide showed excellent correla-
tion with mitochondrial depolarization achieved in primary ALL
blasts with ABT-199, confirming the on-target BCL-2-dependent
activity of this agent. Notably, an additional four B-ALL and two
out of five precursor T cell ALL (T-ALL) samples likewise demon-
strated BCL-2 dependence. These data indicate that several
phenotypically and genetically distinct ALL subtypes utilize BCL-
2 as a primary pro-survival mechanism (Chonghaile et al., 2014).
Our results suggest that the presence of t(4;11) may predict
response to ABT-199 in ALL. We found that the human MLLr
B-ALL cell lines expressed the highest levels of BCL-2 protein
and exhibited the greatest sensitivity to ABT-199 among the
cell lines tested. Among the primary B-ALL samples tested, all
MLLr were highly sensitive. In addition to its single-agent effi-
cacy, ABT-199 showed beneficial results when combined with
induction-type conventional chemotherapy in PDX models of
B-lineage MLLr ALL established from patient-derived leukemia
cells. In four separate in vivo experiments, short-term ABT-1992724 Cell Reports 13, 2715–2727, December 29, 2015 ª2015 The Autreatment (7–10 doses) had only transient anti-leukemia effects,
yet it profoundly enhanced efficacy of the VXL chemotherapy
regimen. The synergistic response between ABT-199 and
chemotherapy treatment is likely to be complex and not due to
a single factor. Previous studies have documented synergistic
anti-leukemia efficacy of dual BCL-2/XL inhibitor ABT-737 in
ALL cells, including xenograft models upon combination with
VXL, the regimen used here (Kang et al., 2007); this synergy
was attributed to the ability of L-ASP to downregulate MCL-1
protein levels (High et al., 2010). Further, anti-mitotic agents
have been shown to synergize with BH3 mimetics and reduce
MCL-1 protein levels (Chen et al., 2011; Leverson et al., 2015;
Tan et al., 2011; Wong et al., 2012), at least in part through phos-
phorylation and proteasomal degradation of MCL-1 during
mitotic arrest (Wertz et al., 2011). Our data inMLLr cell lines sup-
port these findings, demonstrating downregulation of both
MCL-1 and BCL-XL by these agents. The regulation of the
FAF-1 locus byMLL/AF4 presents another interesting possibility.
High FAF1 protein levels are able to enhance apoptosis, and
FAF1 protein is degraded upon induction of apoptosis (Menges
et al., 2009). This suggests thatMLL/AF4-mediated FAF1overex-
pression could sensitize t(4;11) cells to induction of apoptosis by
factors such as L-ASP, as long as the anti-apoptotic activity of
BCL-2 is also inhibited by ABT-199. This could further explain
synergy between BCL-2 antagonist and standard chemothera-
peutic agents used in ALL regimens seen in our studies.
In summary, our findings demonstrate that BCL-2 is a direct
target of the rearranged MLL in ALL cells, translating into
BCL-2 dependence and vulnerability to selective, on-target
BCL-2 inhibition by the clinically active agent ABT-199. These
findings strongly advocate introduction of ABT-199, which
recently demonstrated impressive efficacy in CLL trials, into
the clinical armamentarium of ALL therapy.
EXPERIMENTAL PROCEDURES
Reagents
ABT-199 and ABT-737 were provided by AbbVie.
Cell Lines, siRNA, Primary Samples, and Cultures
Cell lines used for this study are detailed in the Supplemental Experimental
Procedures. MLL/AF4 siRNA experiments were performed as described by
Thomas et al. (2005), with differences noted in the Supplemental Experimental
Procedures. All animal experiments were reviewed by institutional animal
committees. All work with human samples was approved by the institutional
review board at the University of Texas MD Anderson Cancer Center and
the Dana-Farber Cancer Institute. Primary samples were derived from patients
with ALL after informed consent was obtained in accordance with institutional
guidelines set forth by the MD Anderson Cancer Center and Dana-Farber
Cancer Institute. Clinical sample information is summarized in Table S1.
Western Blot Analysis
Western blot analysis was performed as previously described (Pan et al., 2014;
Wilkinson et al., 2013). Antibody sources are listed under Supplemental Exper-
imental Procedures.
RPPA
Expression of pro- and anti-apoptotic BCL-2 family proteins was studied in
186 patients diagnosed with ALL by RPPA. Antibodies used are listed in Table
S4. The methodology and validation of RPPA are described elsewhere (Korn-
blau et al., 2011).thors
BiFC
Interactions between anti-apoptotic proteins BCL-2, BCL-XL, and MCL-1 and
pro-apoptotic proteins BIM andNOXAwere studied by BiFC (Vela et al., 2013).
ChIP Assays and ChIP-Seq
ChIP and ChIP-seq experiments were performed as described in the Supple-
mental Experimental Procedures and as previously described (Milne et al.,
2009; Wilkinson et al., 2013).
Intracellular BH3 Profiling of Primary ALL Cells
Intracellular BH3 profiling on primary ALL cells was performed as previously
described (Pan et al., 2014).
In Vivo Murine Leukemia Models
ALL-236-GFP/LUC cells generated from pre-B-ALL with t(4;11) (Terziyska
et al., 2012) and ICN3 xenograft cells generated from a child with relapsed
MLLr pre-B-ALL (Duy et al., 2011) were injected intravenously into nonobese
diabetic-severe combined immunodeficiency (NOD SCID)/IL2Rg-KO (NSG)
mice. Mice were treated with vehicle (Phosal 50 PG/polyethylene glycol
[PEG]40/ethanol, 60/30/10 v/v) or ABT-199 (100 mg/kg/day) by oral gavage.
For the combination model, an induction-type regimen consisting of VCR, L-
ASP, and DEXA (VXL) (Szymanska et al., 2012) was used in NOD Cg-Rag1tm1-
Mom IL2rgtm1Wjl/SzJ (NRG) mice.
Statistical Analysis
Data were analyzed by the two-tailed Student’s t test or the Mann-Whitney
test, if appropriate. Differences were considered statistically significant at
p < 0.05. Unless otherwise indicated, data are expressed as mean ± SD.
Additional details on experimental procedures are included in the Supple-
mental Experimental Procedures.
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